Lineage Cell Therapeutics
  • Company
    • About Us
    • Leadership
    • Board of Directors
    • Careers
    • Contact
  • Pipeline
    • Overview
    • OpRegen® (Dry AMD)
    • OPC1 (Spinal Cord Injury)
    • Other Programs
  • Technology
    • Lineage Platform
    • Manufacturing
  • Media
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Charters and Documents
      • Leadership
      • Board of Directors
      • Committee Composition
    • Analyst Coverage
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Financials & Filings
      • SEC Filings
      • Annual Report and Proxy Information
      • 2018 AgeX Form 10 and Information Statement
      • 2019 Form 8937
    • E-mail Alerts
    • Contact IR
  • Menu Menu
  • Twitter
  • LinkedIn
  • Facebook
  • Youtube
InterviewsPresentationsKOLsPerspectives
PreviousNext

Interviews, Articles & Podcasts

Please review our forward looking statements on articles, podcasts or recordings

Labiotech
CEO Brian Culley joins the podcast to discuss treating spinal cord injuries with stem cells.

March 28, 2025

Jake Javier on CNN

January 24, 2025

Can Cell Therapy Reverse Hearing Loss?

Brian Taylor, AuD of This Week in Hearing speaks with Lineage CEO Brian Culley about the ReSonance™ Program

January 6, 2025

Revolutionizing Medicine with Cell Therapy

Solomon Wilcots of Russo partners speaks with Lineage CEO Brian Culley

October 16, 2024

BioTech Nation … with Dr. Moira Gunn
Brian Culley, CEO, talks about a new approach to treating diseases which replaces damaged cells with new ones.

October 16, 2024

San Diego Business Journal

San Diego Business Journal
Lineage Looking to Restore Sight, Hearing, Movement

October 10, 2024

Labiotech
CEO Brian Culley discusses the OPC1 program and the challenges associated with clinical trials in the SCI space

October 7, 2024

BioTechTV
CEO Brian Culley describes the idea behind organizing the Spinal Cord Injury Investor Symposium and gives an overview of Lineage’s cell therapy approach

June 26, 2024

Business of BioTech
CEO Brian Culley met with @mattpillar on the Business of Biotech Podcast to share insights into our spinal cord injury program and our journey of innovation and resilience.

June 24, 2024

Drug Target Review
The evolution of cell therapy to address unmet medical needs

June 19, 2024

Presentations from specific events, conferences, or showcases

X Spaces Event

Hosted by @GeneInvesting

November 15, 2023

Eyecelerator 2023

“Mapping the Future of Geographic Atrophy”

November 2, 2023

H.C. Wainwright Global Investment Conference

View Presentation

May 24, 2022

Key opinion leaders discuss topics related to Lineage’s clinical programs

Watch the video on CGTLive.com

Richard Fessler, MD, Professor of Neurosurgery, Rush University Medical School, discusses data seen in the phase 1/2 clinical trial of OPC1 for spinal cord injury (watch on CGTLive.com)

July 20, 2022

Review of the pathogenesis of AMD and the pathways to CNV and GA

Jordi Monés, M.D., Ph.D., Director, Institut de la Màcula and Director, Principal Investigator and Founder, Barcelona Macula Foundation

OpRegen® Phase 1/2a Clinical Study Results
2020 ARVO Meeting

Christopher D. Riemann, M.D., Cincinnati Eye Institute (CEI)

Why is dry age-related macular degeneration (dry AMD) research so important?

Allen C. Ho, M.D., Wills Eye Hospital Director of Retina Research

Why is spinal cord research so important?

Dr. John Steeves, Emeritus Principal Investigator @ICORD and Professor @UBC

A selection of patient focused media related to our cell therapy programs

The Stem Cellar
The Official Blog of CIRM, California’s Stem Cell Agency

Where Are They Now: Jake Javier

Pioneering Cell Transplants for the Treatment of Spinal Cord Injury
Christopher and Dana Reeve Foundation Blog

OPC1 Patient Spotlight – Chris Block – Part 1

In 2016, Chris Block was paralyzed in a bicycling accident. In 2023, he is an avid scuba diver, horseback rider and, importantly, has his independence.

OPC1 Patient Spotlight – Chris Block – Part 2

In 2016, Chris Block was paralyzed in a bicycling accident. In 2023, he is an avid scuba diver, horseback rider and, importantly, has his independence.

CDRF Blog SCI

Patients Making Strides in Advancing SCI Research
Christopher and Dana Reeve Foundation Blog

The Stem Cellar
The Official Blog of CIRM, California’s Stem Cell Agency

Update on spinal cord injury patient Jake Javier, enrolled in CIRM-funded stem cell clinical trial

OPC1 Program – Patient Spotlight – Jake Javier

In 2016, Jake Javier was paralyzed from the neck down. In late 2022, he is set to graduate from Duke University with his Master’s Degree in Biomedical Engineering, with plans to help those impacted by neurological injuries or diseases.

Sonia Cohen’s OpRegen Story

OpRegen for Dry AMD | Lineage Cell Therapeutics

Cheri’s Story

OpRegen for Dry AMD | Lineage Cell Therapeutics

WDAM7 Mississippi

“New Treatment for Age-Related Dry Macular Degeneration”

5 years through the eyes of a mum.

A powerful dramatization of living with the progression of vision loss related to AMD. Source: www.macularsociety.org

Spinal Cord Injury and Lineage’s OPC1 Cell Therapy

An instructive whiteboard video explaining how spinal cord injury disrupts normal bodily function as well as OPC1 administration and mechanism of action.

OPC1 Program – Patient Spotlight – Kris Boesen and Lucas Lindner

Highlighting the progress made by Kris Boesen and Lucas Lindner, both of whom received Lineage’s OPC1 cell therapy following traumatic spinal cord injury (SCI).

Lucas Lindner was paralyzed from the neck down following a car accident. The next year, he threw out the first pitch at a Major League Baseball game.

Watch the video above to learn more about Lucas’ journey.

© Copyright - Lineage Cell Therapeutics, Inc.   |   Terms of Use & Privacy   |   [email protected]
  • Twitter
  • LinkedIn
  • Facebook
  • Youtube
Scroll to top